Related Experiment Video
Updated: May 31, 2026
Assessing Intracardiac Vortices with High Frame-Rate Echocardiography-Derived Blood Speckle Imaging in Newborns
Published on: December 22, 2023
The Use of Levosimendan in Infants With Heart Disease: A Scoping Review
1Author Affiliation: University of Pennsylvania, Philadelphia, PA (Tan).
Insights
Levosimendan shows potential benefits for infants with heart disease, improving key indicators but with inconsistent cardiac outcomes. Further large-scale trials are needed to confirm its effectiveness and safety in this population.
Area of Science:
- Pediatric Cardiology
- Neonatal Critical Care
- Pharmacology
Background:
- Levosimendan is an innovative inotrope with limited research on its use in infants.
- Understanding levosimendan's safety and efficacy in neonates with heart conditions is crucial.
Purpose of the Study:
- To conduct a scoping review of existing literature on levosimendan use in infants with heart disease.
- To evaluate the current evidence regarding levosimendan's safety and efficacy in the pediatric population.
Main Methods:
- Comprehensive literature search of PubMed, Cinahl, Embase, and Scopus (2016-2025).
- Inclusion of primary research on infants receiving levosimendan, excluding adult/older pediatric studies.
- Data extraction focused on levosimendan therapy outcomes in the neonatal/infant population.
Main Results:
- Levosimendan improved lactate levels, central venous oxygen saturation, and left ventricular function.
- Cardiac outcomes showed inconsistency across studies, necessitating further investigation.
- Adverse events were rare and manageable, including arrhythmias and hypotension.
Conclusions:
- Large, multicenter, randomized controlled trials are required to establish levosimendan's effectiveness in infants.
- Standardized protocols are essential for future research in neonatal populations.
- Nurses play a vital role in advancing ethical, patient-centered research and care for infants.
Background:
Although levosimendan is a promising and innovative inotrope for adults with heart disease, limited research has been conducted to demonstrate its safety and efficacy in infants.
Purpose:
This scoping review evaluates the current state of literature regarding the use of levosimendan in infants with heart disease.
Data Sources:
A comprehensive literature search was conducted across PubMed, Cinahl, Embase, and Scopus databases for studies published between January 2016 and February 2025.
Study Selection:
Inclusion criteria included primary research studies involving the neonatal/infant population, evaluation of levosimendan therapy, written in English, and published within the last decade. Studies that primarily examined older pediatric or adult populations were excluded. Initial database searches yielded 310 articles. Duplicates were removed and titles, and abstracts were screened. Fourteen articles met the full-text review criteria.
Data Extraction:
The author independently extracted data to map the scope of available evidence, with a focus on understanding findings related to levosimendan therapy in the target population.
Results:
Levosimendan was associated with improvements in lactate levels, central venous oxygen saturation, and left ventricular function. Despite these benefits, cardiac outcomes were inconsistent across studies. Safety profiles were favorable, with rare but manageable adverse events such as arrhythmias and hypotension.
Implications For Practice And Research:
Large, multicenter, randomized, controlled trials with standardized protocols are needed to evaluate the effectiveness of levosimendan in neonatal/infant populations. Nurses are essential in promoting ethical, patient-centered, and evidence-based clinical research and care for this vulnerable population.
Related Concept Videos
01:29Drug Dosing: Infants and Children
01:26Heart Failure Drugs: Inotropic Agents
01:26Mitral Stenosis III: Medical Management
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:30Heart Failure V: Medical Management
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications